Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Post by Madmanmadoxon Mar 16, 2018 3:53pm

200 Views

Post# 27730487

I have a small bid at 33 cents that just got filled

Averaging up from my 20 cent cost...... Put me to 150,000 shares even.

Good Luck to everyone next week! I truly hope this drug helps to better the lives of all of us, especially the ones (loved ones) that currently have to take Naproxen as no better alternative yet exists.

I'll drink tommorow to all ye longs, like me, who invest in companies and people like Wallace, that inturn spend their life towards building a brighter/healthier future for all of us. :)

Bullboard Posts

Thesis Gold makes high-grade discovery at Ring Zone